Overview

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Capecitabine
Epirubicin
Oxaliplatin